These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16640121)

  • 41. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers.
    Tcheremissine OV; Castro MA; Gardner DR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):7-14. PubMed ID: 22059602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Approaches to the development of the Japanese academic version of the MATRICS Consensus Cognitive Battery].
    Sato T; Sora I
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):241-4. PubMed ID: 22256613
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.
    Keefe RS; Mohs RC; Bilder RM; Harvey PD; Green MF; Meltzer HY; Gold JM; Sano M
    Schizophr Bull; 2003; 29(1):45-55. PubMed ID: 12908660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Building a neurocognitive profile of thought disorder in schizophrenia using a standardized test battery.
    Tan EJ; Rossell SL
    Schizophr Res; 2014 Jan; 152(1):242-5. PubMed ID: 24291545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge.
    McGlashan TH; Carpenter WT
    Schizophr Bull; 2007 Sep; 33(5):1086-92. PubMed ID: 17634414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 48. Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia.
    O'Halloran JP; Kemp AS; Gooch KN; Harvey PD; Palmer BW; Reist C; Schneider LS
    Schizophr Res; 2008 Nov; 106(1):33-41. PubMed ID: 18160262
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cognitive impairment in schizophrenia: how experimental models using nonhuman primates may assist improved drug therapy for negative symptoms.
    Rupniak NM; Iversen SD
    Neuropsychologia; 1993 Oct; 31(10):1133-46. PubMed ID: 7904732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
    Preskorn SH; Gawryl M; Dgetluck N; Palfreyman M; Bauer LO; Hilt DC
    J Psychiatr Pract; 2014 Jan; 20(1):12-24. PubMed ID: 24419307
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cognitive impairment in late life schizophrenia: a suitable case for treatment?
    Howard R
    Int J Geriatr Psychiatry; 1998 Jun; 13(6):400-4. PubMed ID: 9658275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol.
    Addington J; Addington D
    Can J Psychiatry; 1997 Nov; 42(9):983. PubMed ID: 9429073
    [No Abstract]   [Full Text] [Related]  

  • 54. [Cognitive dysfunction in schizophrenia--new therapeutic possibilities. 11th ECNP. 31 October-4 November 1998, Paris].
    Fortschr Neurol Psychiatr; 1998 Dec; 66(12 Suppl):1-4. PubMed ID: 9926343
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of add-on cilostazol on cognition in patients with schizophrenia: an open-label pilot trial.
    Shirayama Y; Konishi T; Hashimoto K
    J Clin Psychopharmacol; 2011 Oct; 31(5):659-61. PubMed ID: 21881450
    [No Abstract]   [Full Text] [Related]  

  • 56. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.
    Jarskog LF; Lowy MT; Grove RA; Keefe RS; Horrigan JP; Ball MP; Breier A; Buchanan RW; Carter CS; Csernansky JG; Goff DC; Green MF; Kantrowitz JT; Keshavan MS; Laurelle M; Lieberman JA; Marder SR; Maruff P; McMahon RP; Seidman LJ; Peykamian MA
    Schizophr Res; 2015 May; 164(1-3):136-42. PubMed ID: 25728831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
    Trampush JW; Lencz T; DeRosse P; John M; Gallego JA; Petrides G; Hassoun Y; Zhang JP; Addington J; Kellner CH; Tohen M; Burdick KE; Goldberg TE; Kane JM; Robinson DG; Malhotra AK
    Schizophr Bull; 2015 Nov; 41(6):1237-47. PubMed ID: 26409223
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
    Stroup TS; McEvoy JP; Swartz MS; Byerly MJ; Glick ID; Canive JM; McGee MF; Simpson GM; Stevens MC; Lieberman JA
    Schizophr Bull; 2003; 29(1):15-31. PubMed ID: 12908658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.